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progression and bevacizumab 7.5 mg/kg was administered until progression. The 
model estimated average survival, PFS, drug and administration costs and total costs 
per patient treated with BCG or CVC. RESULTS: BCG treatment results in a mean 
survival of 1.51 years versus 1.38 years with CVC. Both drug and administration costs 
were lower with BCG than CVC and the mean total cost per patient treated with BCG 
was less costly than CVC (a33,153 versus a40,700, respectively). CONCLUSIONS: 
BCG, compared with CVC, gives a greater clinical beneﬁt and is less costly. Therefore, 
BCG is dominant over CVC and should be considered to be therapy of choice for 
treating patients with advanced NSCLC.
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OBJECTIVES: Implemented in several countries, biennial Guaiac Fecal Occult Blood 
Test (FOBT) is used as mass screening for Colorectal Cancer. Using Guaiac FOBT as 
the reference strategy, we estimated the cost-effectiveness of three screening alterna-
tives: biennial Immunological FOBT, Computed Tomography Colonoscopy every 5     
and 10 years (respectively CTC-5 and CTC-10). METHODS: Over a 30-year horizon 
and from the perspective of a third-party payer, we developed a partially observed 
Markov model on a hypothetical cohort of 100,000 subjects at average risk for 
colorectal cancer. Costs were based on French data. Epidemiological parameters were 
from the international literature. The incremental net beneﬁt framework was used to 
describe our results. Then, we performed univariate and probabilistic sensitivity analy-
ses. RESULTS: Compared with Guaiac test strategy, each alternative led to an increase         
in both discounted costs and life-years gained (LYG). The optimal strategy was       
 function of the willingness to pay (WTP). Immunological FOBT resulted in lower   
prevention rate (14%) than CTC-5 (38%) or CTC-10 (24%). However, the two-year 
frequency of Immunological FOBT enabled an earlier detection of cancers conducing 
to higher number of LYG than CTC-10. Outcomes were sensitive to adherence rates.       
Probabilistic sensibility analysis suggested that below a WTP of 1,807a/LYG, the refer-
ence strategy was optimal whilst CTC-10 was preferred between a1807 and a8124 /
LYG. Beyond a WTP of a8124/LYG, CTC-5 provided the highest incremental net 
beneﬁt. Although, Immunological FOBT was subject to extended dominance, it was 
still optimal for one third of the simulations for a WTP between a15,000 and 
a120,000/LYG. This result was due to close expected net beneﬁts between Immuno-
logical FOBT and CTC-5 and induced uncertainty in the choice of the optimal strat-
egy. CONCLUSIONS: From a reasonable willingness to pay of the third-party payer, 
Guaiac FOBT strategy was no longer optimal for colorectal cancer mass screening.
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LONG TERM COST-EFFECTIVENESS OF DOCETAXEL PLUS 
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OBJECTIVES: An economic model was constructed to assess the cost effectiveness of           
docetaxel/cyclophosphamide (TC) compared with doxorubicin/cyclophosphamide 
(AC) as adjuvant treatment for women with operable breast cancer. An Australian 
government perspective was adopted for the analysis. METHODS: A cost utility   
analysis was undertaken for a model population of women with operable breast 
cancer. The median age at baseline was 51 years. Four cycles of docetaxel (75 mg/m 2) 
plus cyclophosphamide (600 mg/m 2) were compared to four cycles of doxorubicin 
(60 mg/m 2) plus cyclophosphamide (600 mg/m 2). Seven year overall survival and 
disease free survival results were utilised from a pivotal randomised control trial (Jones 
et al, 2009). Overall survival was extrapolated to a 35 year model horizon. Utility 
weights were derived from a valuation study conducted in an Australian general 
population sample. Expert opinion garnered from a treatment practice survey of 
clinicians informed the average frequency and type of resources required for diagnosis 
and treatment of recurrence of disease. RESULTS: Adjuvant treatment of operable    
breast cancer with TC was associated with incremental costs of A$6253, and 
incremental QALYs (Quality Adjusted Life Years) of 0.48 (at 35 years) when compared 
to AC. The incremental cost–effectiveness ratio was estimated at approximately 
A$13,000 per QALY when assessed at 35 years. CONCLUSIONS: We found TC to    
be a highly cost effective intervention as adjuvant treatment of operable breast cancer 
when compared with AC in the Australian setting.
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OBJECTIVES: To develop a cost-effectiveness analysis to compare docetaxel vs 
docetaxeltrastuzumab as ﬁrst line therapy in the treatment of patients with advanced 
or metastatic breast cancer HERneu from the public health system Perspective in 
Mexico. METHODS: A markov model was built in order to simulate the clinic course 
of a cohort of patients with metastatic breast cancer HERneu in treatment with 
docetaxel vs docetaxeltrastuzumab as ﬁrst line treatment. The model include 
three health states (without progression, progression and death), with a 12- month 
following. Conceptual frame and clinical course was based on literature review and 
controlled clinical trials. In order to deﬁne resources and procedures to set costs, a 
literature search for economic evaluation and different disease management alterna-
tives was done. The drugs costs were obtained from the costs of purchasing published 
by the Mexican Institute of Social Security and included diagnosis, treatment, follow-
ing and medical support. The clinical beneﬁt of the treatment is to be determined by 
Progression-Free Survival (PFS). RESULTS: Using docetaxeltrastuzumab 49.1% of 
patients were free of progression and 25.6% of those who used only docetaxel during 
the 12 months of management; In other words, to maintain a patient free of progres-
sion at 12 moths is necessary to treat 2.04 and 3.91 patients with docetaxeltrastuzumab 
and docetaxel respectively. The expected cost with docetaxeltrastuzumab is 
US$32,460.87 and with docetaxel US$22,735.74. The cost to maintain a patient free 
of progression at 12 moths is US$66,085.92 and US$88,899.50 (mean cost effective-
ness ratio) and the ICER is US$41,305. CONCLUSIONS: Results show that 
docetaxeltrastuzumab is a cost effective therapy when comparing with docetaxel in 
ﬁrst line therapy for patients with metastatic breast cancer.
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HEALTH ECONOMICS OF HPV VACCINATION IN AUSTRIA—COST-
EFFECTIVENESS OF VACCINATING 12 YEAR OLD GIRLS
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OBJECTIVES: Because of an unfavorable health economics assessment commissioned 
by the Ministry of Health, in Austria HPV vaccination costs are not covered by the 
government. We have performed an additional assessment based on essentially the 
same cost data and only slightly different assumptions concerning infection and disease 
propagation but simulating cohorts for their whole life expectancy. METHODS: The 
applied model is of a hybrid type. The dynamic infection model was formulated as a 
SIR model with delayed transition from the recovered state into the susceptible state. 
It was validated by comparison with empirical infection rates for the different HPV 
strains within age groups. Vaccination of 85% of 12 year old girls was modeled. Two 
equally sized cohorts of girls were followed from birth to 100 years of life, one vacci-
nated against HPV types 16 and 18 and one unvaccinated, both were assumed to have 
unchanged opportunistic screening. All estimates were based on 1000 runs of these 
cohorts. The infection model was validated by comparison of the unvaccinated cohort 
with the Austrian incidence and mortality data for the years 2002 to 2007. RESULTS: 
Vaccination of 85% of 12 year old girls resulted in a decrease of mortality by 64% and 
incidence by 69%. Cervical intraepithelial neoplasias (CIN) were reduced too: 27%, 
46% and 49% for CIN1 to CIN3, respectively. Without discounting vaccination was 
cost saving. Assuming discount rates between 2 and 6% the incremental cost-effective-
ness ratio (ICER) was 6,000.- to 21,000.- a/LYG. Sensitivity analyses demonstrate that, 
except for discount rates, a booster vaccination and no cross-protection against 
non-vaccine types has the greatest inﬂuence on ICER. CONCLUSIONS: Also for the 
Austrian health care system vaccination is cost-effective in the long run, although it’s 
full economic impact is—concerning cervical cancer—seen only after decades.
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OBJECTIVES: To estimate the cost-effectiveness of docetaxel for breast cancer treat-
ment in adjuvant and metastatic settings. Three comparisons are performed: 3 cycles 
of ﬂuorouracil, epirubicin and cyclosphophamide followed for 3 cycles of docetaxel 
(3FEC100-3D) versus 6 cycles of ﬂuorouracil, epirubicin and cyclosphophamide 
(6FEC100); 6 cycles of ﬂuorouracil, doxorubicin and cyclosphophamide (FAC) versus 
6 cycles of docetaxel, doxorubicin and cyclosphophamide (TAC), both as adjuvant 
treatments; and docetaxel versus paclitaxel in metastatic breast cancer (MBC). 
METHODS: The lifetime Markov model used for the adjuvant setting analysis, 
developed by Aremis Consultants, considers 6-month cycles and 4 health states: no 
recurrence; loco-regional recurrence; metastatic recurrence; and death. The model for 
MBC, created by United Bio Source, lasts for 10 years with 3-week cycles and 3 health 
states: no progression; progression; and death. Transition probabilities were derived 
from head-to-head clinical trials. Direct medical costs were estimated for the Society 
and the tertiary cancer centre Instituto Português de Oncologia de Lisboa (IPOL) 
perspectives. Resource consumption was based on clinical practice at IPOL (patient-
level data). Unit costs were derived from ofﬁcial sources and IPOL data. RESULTS: 
The projected survival advantage was 0.93 years for TAC compared to FAC, with an 
incremental cost of a8369 for the Society and a8031 for IPOL, and 0.49 years for 
3FEC100-3D compared to 6FEC100, with incremental costs below a3700 for either 
perspective. In both cases, incremental costs per life year gained (ICER) are below 
a9000. In MBC, the predicted incremental life expectancy with Docetaxel is 6 months, 
being the incremental cost of around a11,000 for either Society or IPOL. The ICER 
is a21,905 and a22,329, respectively. Sensitivity analysis shows that these ﬁndings are 
only responsive to changes in the relative clinical gains of docetaxel. CONCLUSIONS: 
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Docetaxel is cost-effective and should be used as adjuvant treatment and considered 
as therapeutic option for MBC.
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COST-EFFECTIVENESS OF BEVACIZUMAB COMBINATION THERAPY IN 
METASTATIC COLORECTAL CANCER: RESULTS OF MARKOV COHORT 
SIMULATION FROM A SOCIAL PERSPECTIVE IN KOREA
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OBJECTIVES: Bevacizumab, known as VEGF inhibitor, has demonstrated signiﬁcant 
activity when it is used with cytotoxic chemotherapy together in metastatic colorectal 
cancer(mCRC). However, bevacizumab is an expensive medication known as not 
cost-effectiveness with high ICER(Incremental Cost-Effectiveness Ratio) in other coun-
tries. The purpose of this study was to examine the economic efﬁciency of treating 
mCRC with bevacizumab plus chemotherapy versus chemotherapy alone from the 
perspective of the social aspects in Korea. METHODS: Markov model was developed 
to compare the cost and beneﬁts of adding bevacizumab to oxaliplatin plus FU/
LV(FOLFOX) or capecitabine plus FU/LV(CapeOX) with FOLFOX or CapeOX 
alone. We searched clinical documentation, extracted median time to progression and 
median overall survival from each chemotherapy, and calculated the transition prob-
ability and death rate per cycle. Model simulates costs and outcomes in hypothetical 
cohort of metastatic colorectal cancer for 5 years with 5% discount rate. We included 
that direct and non-direct medical cost(2009). The ICERs were calculated from incre-
mental life-years gained(LYG) and incremental costs between single and combination 
therapy. Sensitivity analyses were performed on crucial parameters. RESULTS: 
After markov model simulation for 5 years, FOLFOXbevacizumab gained 1.58 
years/patient and FOLFOX 1.42 years/patient, whereas CapeOXbevacizumab 1.57 
years/patient and CapeOX 1.31 years/patient. Total cost of FOLFOXbevacizumab, 
FOLFOX, CapeOXbevacizumab, CapeOX are W88,567,199($70,854), 
W73,938,752($59,151), W91,904,773($73,524), W43,864,530($35,092), respec-
tively. The ICERs of additional bevacizumab when combined with FOLFOX, CapeOX 
were W89,974,151 ($71,979), W181,331,641 ($145,065), respectively, per life year 
gained, proving very high in both case combination therapy. Sensitivity analysis 
showed that the price of bevacizumab is a key parameter of its cost-effectiveness. 
CONCLUSIONS: As a result, it is proven that the addition of bevacizumab to 
FOLFOX, CapeOX in mCRC patients is expensive given clinical beneﬁt in terms of 
LYG in Korea. This ﬁndings may offer one of the useful basic data selecting chemo-
therapy regimens in treating for mCRC.
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OBJECTIVES: Colorectal cancer (CRC) is the third most common cancer in the 
UK. In 2007 the UK NHS introduced a CRC screening programme using the faecal 
occult blood test (FOBT) for biennial screening of individuals aged 60 to 69. CT 
colonography (CTC) is an alternative technology for CRC screening with the potential 
to prevent cancer by detecting pre-cancerous polyps as well as detecting cancer at an 
early stage. This economic analysis assessed the cost-effectiveness of CTC for CRC 
screening from the UK NHS perspective. METHODS: A state-transition Markov 
model was constructed to simulate the lifetime experience of a cohort of individuals 
screened under a range of scenarios using four different CRC screening technologies: 
FOBT, ﬂexible sigmoidoscopy, optical colonoscopy and CTC. The model estimated 
lifetime costs and health outcomes; the cost-effectiveness measure was incremental 
cost per Quality Adjusted Life Year (QALY). The impact of uncertainty in underlying 
model parameters was evaluated in one-way and probabilistic sensitivity analyses. 
RESULTS: CTC screening every 10 years for individuals aged 60–69 was less expen-
sive and yielded greater health beneﬁts (QALYs and life years) compared to no screen-
ing or the current UK programme of biennial FOBT screening. Compared to biennial 
FOBT, 10-yearly CTC screening for 60–69 year olds is estimated to avoid 661 more 
cases of CRC and 364 more deaths per 100,000 people invited for screening. CTC 
was cost-effective under a range of assumptions. The model ﬁt to observed epidemiol-
ogy data well, and was robust to changes in underlying parameter values. CONCLU-
SIONS: CTC has the potential to provide a cost-effective option for CRC screening 
and may be cost saving compared to the current programme of biennial FOBT.
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OBJECTIVES: Although several clinical and biological parameters are prognostic 
factors, their medico-economic impact in the prescription of erlotinib has never been 
evaluated. A French NCI prospective study aimed to determine the cost of manage-
ment of advanced NSCLC patients (pts) treated by erlotinib and to evaluate the cost-
effectiveness ratio in populations selected on clinical-guided or biomarkers-guided 
arguments. METHODS: Prospective cohort of consecutive advanced NSCLC pts 
newly treated by erlotinib and followed until progression or death. Direct medical 
costs, including erlotinib and hospitalization costs were computed from the health 
care system perspective with a time horizon of 2 years. Cost-effectiveness ratios (CER) 
were calculated as management cost divided by the number of days of life remaining 
(DOLR) when the treatment is initiated, in all patients, in clinical-selected patients 
(non/ex-smoking women with non-squamous cell carcinoma (SCC) histology) and in 
biomarker-selected patients. RESULTS: A total of 522 patients were enrolled between     
02/07 and 03/08. Median age was 62 years; 32% were females; 63% had adenocar-
cinoma. With a 15.5 months (mo.) median follow-up, median PFS and OS were 
respectively 2.4 and 5.6 mo. Mean management cost was 10284       o a8562 per patient, 
with a median of 170 days remaining to live at initiation of erlotinib treatment (a60 /
DOLR). Direct erlotinib cost represented 78% of the cost. Non-smoking women with 
non-SCC histology lived 133 days longer than other patients (279 and 146 days 
respectively), resulting in an extra-cost management of a2637 due to a longer erlotinib 
treatment. CER was however lower (a44/DOLR) in non-smoking women with non 
SCC histology than in other patients (a66/DOLR). CER of biomarkers-selected 
patients will be available for the congress. CONCLUSIONS: Clinical-guided argu-
ments allowed to identify patients with lower management costs per day of life 
remaining to live. Planned analyses would evaluate the impact of biomarkers in term 
of cost of management per day of life remaining.
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WOMEN WITH BREAST CANCER FOR ADJUVANT CHEMOTHERAPY
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OBJECTIVES: Adjuvant chemotherapy is used to reduce the risk of relapse after 
surgery. Its limited efﬁcacy in breast cancer must be weighed against induced toxicities 
and cost. The selection of patients eligible for adjuvant chemotherapy is based 
on prognostic factors. Genomic signatures would improve patient selection for adju-       
vant chemotherapy and avoid overtreatment. The aim of this study is to compare the            
cost -effectiveness of different prognosis -based selection strategies in the French 
context. METHODS: We used a model -based simulation. Population characteristics, 
survival and hospital costs (chemotherapy, chemotherapy -induced toxicities and 
relapses) were estimated using a patient -level data set from a retrospective cohort 
of patients followed -up at Gustave Roussy Institute since 1990. All patients 
were node -negative and metastasis -free after initial surgery. The other model param-
eters (chemotherapy efﬁcacy, sensitivity and speciﬁcity of prognosis -based selection 
strategies) were obtained from literature. The cost analysis was conducted from a 
third -party payer’s perspective. We used a strategy with no adjuvant chemotherapy 
as a reference for cost -effectiveness comparisons. RESULTS: The retrospective 
cohort study consisted of 910 women with breast cancer. The mean age was 57 
(range: 23–93). Thirty-one percent of patients were Scarff -Bloom grade I, 43% 
grade II and 19% grade III (7% grade missing). The mean tumor size was 19 mm 
(range: 1–120). Thirty-two percent of the women received adjuvant chemotherapy 
alone or combined with another adjuvant treatment. The median follow-up after 
surgery was 87 months. The median survival time was 209 months. The distant relapse 
rate was 10.7%. The cost of adjuvant chemotherapy was a3,083 (standard deviation: 
a307) and the cost of distant relapse a33,692 (range: a847–a112,710). Cost -effective-
ness analysis is in progress. Results will be available for the meeting. CONCLUSIONS: 
This is the ﬁrst French study to assess the cost -effectiveness of using prognostic 
information to select women eligible for adjuvant chemotherapy in early breast 
cancer.
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OBJECTIVES: To conduct a cost-effectiveness analysis (CEA) of imiquimod compared 
to no treatment in patients with superﬁcial basal cell carcinoma and contraindication 
to surgical intervention and cryotherapy in Poland. METHODS: This analysis was 
based on a decision model regarding clinical effects of imiquimod in comparison to 
placebo (vehicle cream), obtained from randomized clinical trials. The population was 
deﬁned as adult patients with superﬁcial basal cell carcinoma (sBCC) and contraindi-
cation to surgical intervention/cryotherapy, also patients, who do not give consent to 
these forms of treatment. Clinical and histological complete clearance were assessed 
as health outcomes. Direct medical costs of the analysed therapies were estimated from 
the perspective of both payers in Poland (National Health Fund and patient). We 
included costs of medication, clinic visits and diagnostic assessments. Time horizon 
of the analysis was 18 weeks. Treatment was assumed as once a day 5x/week for 6 
weeks. Costs and effects were not discounted. RESULTS: Probability of complete 
clearance, assessed clinically and histologically was 0.751 for patients treated with 
imiquimod and 0.017 when placebo was used. Probability of histological complete 
clearence was 0.822 and 0.031, respectively. Total costs of imiquimod therapy were 
estimated at 1,075.30 PLN, while costs of no treatment were 174.80 PLN. Incremental 
